News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
822,989 Results
Type
Article (85162)
Company Profile (624)
Press Release (737203)
Section
Business (231597)
Career Advice (4091)
Deals (39619)
Drug Delivery (106)
Drug Development (90365)
Employer Resources (192)
FDA (17848)
Job Trends (17242)
News (394200)
Policy (39560)
Tag
Academia (2970)
Africa (1260)
Alliances (56288)
Alzheimer's disease (1239)
Approvals (17773)
Arizona (200)
Artificial intelligence (72)
Asia (48925)
Australia (8609)
Bankruptcy (392)
Best Places to Work (12222)
Biosimilars (71)
Biotechnology (438)
C2C Services and Suppliers (95111)
California (1791)
Canada (822)
Cancer (480)
Career advice (3498)
Cell therapy (141)
China (134)
Clinical research (70338)
Collaboration (136)
Compensation (74)
COVID-19 (2744)
Cystic fibrosis (76)
Data (280)
Diabetes (67)
Diagnostics (6469)
Drug pricing (66)
Earnings (93190)
Employer resources (162)
Europe (111860)
Events (124724)
Executive appointments (137)
FDA (18007)
Florida (207)
Funding (136)
Gene therapy (105)
GLP-1 (585)
Government (4995)
Healthcare (20592)
Hotbed/Location (534575)
Illinois (279)
Indiana (142)
Infectious disease (2766)
Inflammatory bowel disease (102)
Interviews (804)
IPO (17459)
Job creations (5172)
Job search strategy (2850)
Kansas (100)
Layoffs (464)
Legal (9999)
Lung cancer (109)
Manufacturing (91)
Maryland (413)
Massachusetts (1590)
Medical device (14191)
Medtech (14196)
Mergers & acquisitions (21926)
Metabolic disorders (248)
Michigan (118)
Minnesota (207)
Neuroscience (1392)
New Jersey (548)
New York (550)
NextGen Class of 2024 (7621)
Non-profit (5043)
North Carolina (671)
Northern California (748)
Obesity (142)
Ohio (94)
Opinion (234)
Patents (74)
Pennsylvania (515)
People (63638)
Pharmaceutical (118)
Phase I (21615)
Phase II (30542)
Phase III (23075)
Pipeline (99)
Podcasts (76)
Postmarket research (3529)
Preclinical (9762)
Press Release (72)
Radiopharmaceuticals (237)
Rare diseases (131)
Real estate (7359)
Recruiting (72)
Regulatory (25523)
Research institute (2631)
Resumes & cover letters (645)
South America (1641)
Southern California (710)
Startups (4270)
Texas (206)
United States (8317)
Vaccines (552)
Washington State (263)
Weight loss (142)
Date
Today (54)
Last 7 days (500)
Last 30 days (1929)
Last 365 days (38118)
2024 (26652)
2023 (42566)
2022 (53929)
2021 (58727)
2020 (57671)
2019 (51341)
2018 (39125)
2017 (37193)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36269)
2012 (38416)
2011 (38383)
2010 (39616)
822,989 Results for "iconovir bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
IconOVir Bio to Present at Jefferies Healthcare Conference - May 31, 2023
IconOVir Bio, Inc. today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 4:30 p.m. ET (1:30 p.m. PT).
May 31, 2023
·
1 min read
Drug Development
IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical Trial of its Lead Product Candidate, ICVB-1042
IconOVir Bio, Inc. today announced that the first patient has been dosed in a Phase 1 dose escalation and expansion clinical trial evaluating intravenously (IV) administered ICVB-1042 for the treatment of advanced solid tumors.
July 11, 2023
·
3 min read
Biotech Beach
IconOVir Bio to Present at Oppenheimer 33rd Annual Healthcare Conference
IconOVir Bio, Inc. today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 4:40 p.m. ET (1:40 p.m. PT).
March 7, 2023
·
1 min read
Biotech Beach
IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium
IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the UBS Biotechnology Virtual Private Company Symposium.
September 14, 2022
·
1 min read
Layoffs
IN8bio to Lay Off About 49% of Employees
Facing financial challenges, IN8bio is looking to preserve cash resources through a pipeline prioritization and layoffs at its New York City and Birmingham, Alabama, sites.
September 5, 2024
·
1 min read
·
Angela Gabriel
Biotech Beach
IconOVir Bio to Present Preclinical Data on Lead Candidate ICVB-1042 at SITC 2022
IconOVir Bio, Inc. today announced that it will present preclinical data on ICVB-1042 in three poster presentations at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022), which is being held in Boston, MA and virtually from November 8-12, 2022.
October 5, 2022
·
2 min read
Business
IconOVir Bio Appoints William Kaelin, Jr., M.D., to Board of Directors
IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer, today announced the appointment of William G. Kaelin Jr., M.D., to its Board of Directors.
June 23, 2022
·
3 min read
Business
IconOVir Bio Appoints John Huynh, Ph.D., as Chief Technology Officer
IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced the appointment of John Huynh, Ph.D., as the Company’s first Chief Technology Officer.
June 6, 2022
·
3 min read
BioMidwest
Aruna Bio to Present at BIO International Convention 2024
Aruna Bio, Inc. announced that Stephen From, Chief Executive Officer of Aruna Bio, will be presenting a corporate overview at the 2024 BIO International Convention being held June 3-6, 2024 at the San Diego Convention Center, California.
May 28, 2024
·
1 min read
Collaboration
Novartis, Dren Bio Ink Potential $3B Deal for Anti-Myeloid Bispecific Antibodies for Cancer
Novartis continues its dealmaking spree with a bet on Dren Bio’s Targeted Myeloid Engager and Phagocytosis platform to develop bispecific antibodies in oncology.
July 25, 2024
·
2 min read
·
Tristan Manalac
1 of 82,299
Next